Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)



Status:Enrolling by invitation
Conditions:Neurology, Orthopedic
Therapuetic Areas:Neurology, Orthopedics / Podiatry
Healthy:No
Age Range:4 - 7
Updated:8/30/2018
Start Date:January 2017
End Date:January 2021

Use our guide to learn which trials are right for you!

A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long‑Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

This long-term extension study is an open-label, multiple‑dose study to evaluate the
long‑term safety, tolerability, efficacy and PD of vamorolone administered once daily by
liquid oral suspension over a Treatment Period of 24 months to young boys with DMD who
participated in the VBP15‑002 Phase IIa and VBP15-003 Phase IIa extension core studies.

This study will evaluate if it is safe to use a new medication called vamorolone for more
than two weeks in children with DMD, if boys with DMD who take the study medication have
improved muscle function compared to boys with DMD in other studies who did not take any type
of steroid, and to see if boys with DMD who take the study medication gain less weight
compared to boys with DMD in a prior study who took another type of steroid called
prednisone. Enrolled participants will take the study medication for 24 months.

Inclusion Criteria:

1. Subject's parent or legal guardian has provided written informed consent and HIPAA
authorization (if applicable) prior to any VBP15-LTE long-term extension
study-specific procedures;

2. Subject has previously completed study VBP15-003 up to and including the Week 24 Final
assessments, prior to enrolling in the VBP15-LTE study at the conclusion of the
VBP15-003 Week 24 Visit [Note: if entering the dose-tapering period, subject is
enrolling within 8 weeks after the VBP15‑003 final visit following dose‑tapering]; and

3. Subject and parent/guardian are willing and able to comply with scheduled visits,
study drug administration plan, and study procedures.

Exclusion Criteria:

1. Subject had a serious or severe adverse event in study VBP15-003 that, in the opinion
of the Investigator, was probably or definitely related to vamorolone use and
precludes safe use of vamorolone for the subject in this long-term extension study;

2. Subject has current or history of major renal or hepatic impairment, diabetes mellitus
or immunosuppression;

3. Subject has current or history of chronic systemic fungal or viral infections;

4. Subject has used mineralocorticoid receptor agents, such as spironolactone,
eplerenone, canrenone (canrenoate potassium), prorenone (prorenoate potassium),
mexrenone (mexrenoate potassium) within 4 weeks prior to the first dose of study
medication;

5. Subject has evidence of symptomatic cardiomyopathy. [Note: Asymptomatic cardiac
abnormality on investigation would not be exclusionary];

6. Subject is currently being treated or has received previous treatment with oral
glucocorticoids or other immunosuppressive agents [Notes: Past transient use of oral
glucocorticoids or other oral immunosuppressive agents for no longer than 3 months
cumulative, with last use at least 3 months prior to first dose of study medication,
will be considered for eligibility on a case-by-case basis. Inhaled and/or topical
glucocorticoids prescribed for an indication other than DMD are permitted but must be
administered at stable dose for at least 3 months prior to study drug administration];

7. Subject has used idebenone within 4 weeks prior to the first dose of study medication;

8. Subject has an allergy or hypersensitivity to the study medication or to any of its
constituents;

9. Subject has severe behavioral or cognitive problems that preclude participation in the
study, in the opinion of the Investigator;

10. Subject has previous or ongoing medical condition, medical history, physical findings
or laboratory abnormalities that could affect safety, make it unlikely that treatment
and follow-up will be correctly completed or impair the assessment of study results,
in the opinion of the Investigator

11. Subject is currently taking any investigational drug, or has taken any investigational
drug other than vamorolone within 3 months prior to the start of study treatment.

Note: Subjects may be re-evaluated if ineligible due to a transient condition which would
prevent the subject from participating.
We found this trial at
7
sites
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Barry Byrne, MD
Phone: 352-273-7573
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Durham, North Carolina 27710
(919) 684-8111
Principal Investigator: Edward Smith, MD
Phone: 919-684-1143
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
?
mi
from
Durham, NC
Click here to add this to my saved trials
Chicago, Illinois 60614
Principal Investigator: Nancy Kuntz, MD
Phone: 312-227-3019
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1801 Inwood Rd
Dallas, Texas 75390
(214) 645-3300
Principal Investigator: Diana Castro, MD
Phone: 214-648-5606
University of Texas Southwestern Medical Center UT Southwestern is an academic medical center, world-renowned for...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Davis, California 95616
Principal Investigator: Craig McDonald, MD
Phone: 916-734-4307
?
mi
from
Davis, CA
Click here to add this to my saved trials
Melbourne, 3051
Phone: (03) 9345 4633
?
mi
from
Melbourne,
Click here to add this to my saved trials
13535 Nemours Parkway
Orlando, Florida 32827
(407) 567-4000
Principal Investigator: Richard Finkel, MD
Phone: 407-650-7175
Nemours Children's Hospital Nemours Children's Hospital in Orlando brings pediatric specialty care never before offered...
?
mi
from
Orlando, FL
Click here to add this to my saved trials